We have several ongoing R&D projects at Red Glead Discovery (RGD).
Project Nile aims at developing novel compounds for an epigenetic target in the treatment of cancer. This project is a collaboration between RGD, SARomics Biostructures (SBX) and a research group led by Professor Jonas Nilsson at Sahlgrenska Hospital (Gothenburg, Sweden). Candidate drug development activities are supported by a research grant from Vinnova (the Swedish innovation agency).
Project Ganges, a collaboration between SARomcs Biostructures and RGD, is built on the foundation of a successful fragment screen, where hits for this bromodomain-class target were identified using our exclusive WAC technology. Further validation led to X-ray co-crystal structures revealing a possibility for developing a PPI inhibitor-type molecule. The project is currently in the hit expansion phase and entering hit-to-lead.
A previous project has been spun out into a separate company, Apoglyx, where RGD is a co-owner. Apoglyx research is based on aquaporins, a group of structures in cell membranes discovered in 1991 by Peter Agre and awarded with the Nobel Prize in Chemistry 2003. Aquaporins have been recognized as potential drug targets and may have roles for development of autoimmune diseases, cancer, diabetes, malaria, inflammation and sepsis. The lead compound – RG100204, has shown promising effects against sepsis when evaluated in vivo.
Another area of focus for RGD is on green chemistry. Organic solvents are used to facilitate chemical reactions, but they do not add any value to the final product and in most cases, they originate from petroleum and end up as waste. We have initiated a collaboration with researchers at the Centre for Analysis and Synthesis at Lund University. The project aims to develop methods for organic synthesis in water. Our approach is to recycle water and the catalyst used, so the created waste is close to zero. The long-term goal is to be able to synthesize pharmaceuticals with low environmental impact.